Shares of TNF Pharmaceuticals, Inc. (NASDAQ:TNFA – Get Free Report) dropped 67.2% on Tuesday . The stock traded as low as $0.5401 and last traded at $0.5601. Approximately 9,857,199 shares traded hands during mid-day trading, a decline of 69% from the average session volume of 32,220,806 shares. The stock had previously closed at $1.71.
TNF Pharmaceuticals Trading Up 118.4%
The stock has a market cap of $1.78 million, a P/E ratio of -0.00 and a beta of 2.04. The stock’s 50-day moving average is $2.65 and its 200-day moving average is $3.43.
TNF Pharmaceuticals Company Profile
TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases.
Recommended Stories
- Five stocks we like better than TNF Pharmaceuticals
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for TNF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TNF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
